- Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer.
- The results will be presented as a poster at the AACR Annual Meeting 2021.
- In the study, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients.
- No dose-limiting toxicities were observed, and all adverse events were readily manageable.
- The Phase 1 study was designed to determine the safety and recommended Phase 2 dose of ifabotuzumab.
- Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting the EphA3 receptor. EphA3 is a tumor-restricted antigen expressed in the tumor vasculature and tumor stroma of various solid tumors.
- Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.
- Price Action: HGEN shares are trading 2.8% higher at $17.4 in the premarket session on the last check Friday.
Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.